Adjuvanted vaccine boosts flu protection for elderly

October 16, 2013 by Camilo Mejia Giraldo
Researchers analysed a demographic that has increasing issues with their immune system’s response to vaccines. Credit: BromfordGroup

A recent study has strengthened the current knowledge of the increased effectiveness of adjuvanted flu vaccines in the elderly—a population highly affected by seasonal influenza.

Adjuvants are substances that can be added to vaccines to aid the body's immune response to the .

The 'real world' study, based in Canada, assessed less than 300 elderly for adjuvanted .

It found an MF59 adjuvanted vaccine provided more protection (60 per cent effectiveness) against compared with the unadjuvanted trivalent influenza vaccine.

"We've seen data before that said if you just measure [the patient's] blood anti-body levels, it shows that they do better with the adjuvanted [vaccines]," says Dr Paul Van Buynder, a UWA appointee and co-author of the study.

"What we weren't sure of was whether that would turn into better protection against actual flu, and that is what we were looking at," he says.

Researchers contacted people over 65 years-old who had been routinely lab tested after they had exhibited influenza-like symptoms.

"We have different polices in different parts of British Columbia, some clinics give the adjuvanted vaccines and some do not, so the study was a natural experiment," he says.

After the participants were interviewed, their vaccination status, date and type were confirmed through healthcare records.

Dr Van Buynder says even though adjuvanted vaccines are known to have superior effects, researchers of the study were pleased at the positive results showed by MF59—which is a oil-in-water adjuvant containing a shark oil derivative and two surfactants.

With participants of the study at a median age of 83 years, researchers analysed a demographic that has increasing issues with their immune system's response to vaccines.

"It's a thing called immunosenescence, the older you get, the worse your white cells produce anti-bodies," he says.

"This is a new generation of adjuvants … it actually has an impact on stimulating the antigen production cells, particularly the dendritic cells in the skin area, so they bring a lot more antibodies across to where the vaccine has been administered."

Dr Van Buynder says adjuvanted vaccines are widely used throughout Canada and the EU, but not in the United States or Australia—although some adjuvanted vaccines are licensed in Australia.

"We were looking at what whether in the real world it actually made a difference," he says.

"Because it's one thing to look at the blood levels in a lab and what we wanted to say is that this actually produces a difference."

Explore further: New development could increase flu vaccine supply

More information: www.sciencedirect.com/science/article/pii/S0264410X13010451

Related Stories

New development could increase flu vaccine supply

June 2, 2011

(Medical Xpress) -- Scientists from the U.S. Food and Drug Administration and the pharmaceutical company Novartis announced today in the journal Science Translational Medicine that they have developed a new adjuvant, or compound ...

Recommended for you

Molecular Zika study finds possible target for tests, drugs

April 19, 2016

The molecular structure of the Zika virus as seen on x-ray crystallography revealed electrostatic differences in a key protein compared with other flaviviruses that might explain how it infects human cells, according to a ...

Zika virus may now be tied to another brain disease

April 10, 2016

The Zika virus may be associated with an autoimmune disorder that attacks the brain's myelin similar to multiple sclerosis, according to a small study that is being released today and will be presented at the American Academy ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.